Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial

BACKGROUND: Trastuzumab increases the incidence of cardiac events (CEs) in patients with breast cancer (BC). Dual blockade with pertuzumab (P) and trastuzumab (T) improves BC outcomes and is the standard of care for high-risk human epidermal growth factor receptor 2 (HER2)-positive early BC patients...

Descripción completa

Detalles Bibliográficos
Autores principales: de Azambuja, E., Agostinetto, E., Procter, M., Eiger, D., Pondé, N., Guillaume, S., Parlier, D., Lambertini, M., Desmet, A., Caballero, C., Aguila, C., Jerusalem, G., Walshe, J.M., Frank, E., Bines, J., Loibl, S., Piccart-Gebhart, M., Ewer, M.S., Dent, S., Plummer, C., Suter, T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10044361/
https://www.ncbi.nlm.nih.gov/pubmed/36681013
http://dx.doi.org/10.1016/j.esmoop.2022.100772

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10044361/
https://www.ncbi.nlm.nih.gov/pubmed/36681013
http://dx.doi.org/10.1016/j.esmoop.2022.100772

Ejemplares similares